Bridgewest Appoint Juno Pharmaceuticals as Sales and Marketing Partner

Bridgewest has appointed Juno Pharmaceuticals Pty Ltd (Juno) as Bridgewest’s exclusive sales and marketing partner in Australia and New Zealand for range of widely used sterile injectable products. The marketing rights for the 11 products to be sold and marketed by Juno, were acquired by Bridgewest Perth Pharma Pty Ltd (Bridgewest) with the recently completed the acquisition of the Perth sterile injectable manufacturing facility from Pfizer (Perth) Pty Ltd, a subsidiary of Pfizer, Inc.

Juno sees great potential for the Bridgewest portfolio in the region. There is a strong synergy between the two companies. Juno has a strong focus on the sales of hospital injectable products in the local market. Bridgewest have a high quality sterile injectable manufacturing facility which Juno believe will bring supply stability and innovation to the market.

Bridgewest believes Juno is the ideal commercial partner to assist Bridgewest in launching the LumaCina branded critical hospital products. “We believe there is tremendous potential to re-establish and grow the recently acquired products, in addition to partnering on the expanding pipeline of new products” replied Jon Kafer, President LumaCina and Chief Commercial Officer Bridgewest Perth Pharma.

New Product Launch: Pomolide™ (pomalidomide)

Juno Pharmaceuticals is pleased to announce the launch of Pomolide™ (pomalidomide) oral capsules, in four strengths: 1 mg, 2 mg, 3 mg and 4 mg.

Pomolide™ (pomalidomide) is used to treat relapsed or refractory multiple myeloma.

Juno’s CEO and Managing Director, Mark Crotty, stated that;

“Pomolide™ is an important addition to Juno’s product portfolio, growing our oncology presence to 12 molecules. Pomolide™ is also the second product to utilise our online risk management platform Juno Connected™, which has been receiving excellent feedback from users thus far.”

Pomolide™ (pomalidomide) Product Information

Pomolide™ (pomalidomide) Consumer Medicine Information